Jean-Michel Petit

Peut-on se passer du pétrole en sinspirant du vivant ? Dionymer fait le pari de léconomie circulaire en développant une technologie permettant de transformer les déchets organiques industriels en polymères PHA (polyhydroxyalcanoates) biodégradables à laide de microorganismes. Une réponse élégante et couplée à deux besoins : Réduire le coût de gestion pour les producteurs de biodéchets (agriculteurs, collectivités, agro-alimentaire), et réduire limpact environnemental des industriels utilisant des polymères issus de la pétrochimie pour leur produits.

Precision medicine is the adaptation of a medical treatment to the exact molecular profile of each patient. More generally, it relies on the sophisticated analysis of circulating biomarkers (genetic, protein or cellular) in the blood flow of patients. SmartCatch arises from a research work initiated in 2012 by a team of multidisciplinary scientists from the Laboratory of Analysis and Architecture of Systems (LAAS, CNRS) and urologist surgeons of the IUCT-Oncopole and Toulouse hospital. The results of this work have been patented in February 2015. Carried by four of its inventors, SmartCatch was established in September 2016 and exploits an innovative technology of physical capture of circulating tumor cells. SmartCatch designs capture micro-devices that look like micro-fishnets. These products can be used for early diagnosis of cancer,personnalized therapeutic follow-up and pharmaceutical screening.

Micropep is an innovative plant biotechnology company developing the next generation of biological crop protection solutions based on the incredible potential of micropeptides; short natural peptide molecules that target and regulate plant genes and proteins.

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases. Advicenne have spent more than 10 years developing products for the treatment of rare renal diseases. At Advicenne, we are committed to developing and commercializing medicines that are suitable for both children and adults – groundbreaking treatments for rare diseases should be available to patients of all ages.

FineHeart is a clinical stage medical device company based in Bordeaux, France. Its innovative product, FLOWMAKER®, has the potential to treat 200,000 patients with advanced heart failure each year. FineHeart will initially target the 50,000 most severe patients who are eligible for cardiac assistance. Initial estimates value this market segment to be worth over US$5 billion. FineHeart was founded by CEO Arnaud Mascarell and a team of internationally renowned cardiac surgeons and electro-physiologists, including Dr. Stephane Garrigue, CSO and inventor of the concept, and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy (CRT). The company holds an international portfolio of 147 patents in 25 different families. FineHeart benefits from the support of a wide range of public, private, industrial and independent investors: including the French groups Lauak and Doliam, FineHeart Founders, as well as the investment funds and historical shareholders Aquiti, Broadview Ventures, Galia, Irdi , M Capital, NACO, UI Investment, & Verve Ventures. FineHeart is also financed by the European Union (EIC), Bpifrance and the Nouvelle Aquitaine and Région Centre regions. FLOWMAKER® is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the hearts natural contractions. It respects the natural blood flow and does not require aortic bypass surgery. It is the first miniaturized device - barely 10 cm in size - that is adjustable to patients needs, like a pacemaker, to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, which, on average lasts 90 minutes.

Exagan is a leading supplier of Gallium Nitride based transistor devices for power supply, electrical automotive, solar panel and industrial application. With a unique and proprietary technology, Exagan is accelerating transition of power electronics industry towards more efficient production and conversion systems to reduce CO2 emission, by enabling large scale adoption of GaN on Silicon power technology.

GamaMabs Pharma is a biotechnology company based out of 78 Allees Jean Jaures, Le Pré Catelan – Bâtiment F, Toulouse, Midi-Pyr��n��es, France.

Notre technologie innovante issue de la recherche française (CNRS Bordeaux), permet de fabriquer des billes polymères monodisperses (CV<20 %), très magnétiques (taux d'oxyde de fer >70%), calibrées de 100 à 500 nm (+/- 10 nm), offrant une surface spécifique élevée (5 à 25 m²/g). Ces billes magnétiques sont stables, sensibles et rapidement séparables sous champ magnétique. Ces particules sont particulièrement bien adaptées pour être intégrées dans des dispositifs microfluidiques. Leur surface est, et peut être, fonctionnalisée par le greffage de molécules d'intérêt biologique, afin de capturer, isoler et séparer, analyser ou purifier des entités biologiques (molécules, oligonucléotides, cellules, virus) dans un échantillon total. Les principales applications touchent la purification cellulaires et moléculaires et les immunoanalyses dans le diagnostic in vitro. Nous proposons également des supports magnétiques, des instruments (thermoshaker, pipette électronique à écartement variable) et des automates (d'extraction et de pipetage). Nous étudions toute problématique R&D dans la plus stricte confidentialité, et intervenons sous la forme de contrats pour la réalisation d'études de faisabilité, la fabrication d'échantillons ou la production de lots.

Antabio is a privately-held clinical-stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments for drug-resistant infections due to CDC and WHO critical priority pathogens. Please visit www.antabio.com and follow us on Twitter @antabio

Peut-on se passer du pétrole en sinspirant du vivant ? Dionymer fait le pari de léconomie circulaire en développant une technologie permettant de transformer les déchets organiques industriels en polymères PHA (polyhydroxyalcanoates) biodégradables à laide de microorganismes. Une réponse élégante et couplée à deux besoins : Réduire le coût de gestion pour les producteurs de biodéchets (agriculteurs, collectivités, agro-alimentaire), et réduire limpact environnemental des industriels utilisant des polymères issus de la pétrochimie pour leur produits.

Solvionic is in the business of Ionic Liquids for the past 19 years. Our activity is devoted to the production and marketing of ionic liquids and to the development of new materials and processes based on ionic liquids. We have a well-established track record and our services have always been delivered with great customer satisfaction, with a particular focus on highly pure products. Besides production and sales, R&D is the other main activity of Solvionic. In this context, we assist industrial partners in their projects in the field of synthesis, surface treatments (protective coatings), and electrochemistry (energy storage, electrodeposition, electrochromic devices). Solvionic has several license agreements to supply ionic liquids worldwide (especially those based on TFSI and FSI famous anions). Working on new ionic liquids, and new ionic liquid-based electrolytes as well as materials is part of our commitment to innovation.

Precision medicine is the adaptation of a medical treatment to the exact molecular profile of each patient. More generally, it relies on the sophisticated analysis of circulating biomarkers (genetic, protein or cellular) in the blood flow of patients. SmartCatch arises from a research work initiated in 2012 by a team of multidisciplinary scientists from the Laboratory of Analysis and Architecture of Systems (LAAS, CNRS) and urologist surgeons of the IUCT-Oncopole and Toulouse hospital. The results of this work have been patented in February 2015. Carried by four of its inventors, SmartCatch was established in September 2016 and exploits an innovative technology of physical capture of circulating tumor cells. SmartCatch designs capture micro-devices that look like micro-fishnets. These products can be used for early diagnosis of cancer,personnalized therapeutic follow-up and pharmaceutical screening.

Micropep is an innovative plant biotechnology company developing the next generation of biological crop protection solutions based on the incredible potential of micropeptides; short natural peptide molecules that target and regulate plant genes and proteins.